International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Pilaralisib (Primary) ; Voxtalisib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 01 Mar 2018 Planned End Date changed from 1 Apr 2018 to 6 Jun 2018.
- 01 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 6 Jun 2018.
- 16 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.